Pharmaceutical companies are incorporating EEG (Electroencephalography) more often in their preclinical drug discovery efforts. The high degree of translatability of EEG from rodents to humans makes it ideal to be used in de-risking programmes in drug discovery. In order to develop such a tool, AniTech Limited (Hong Kong) is leveraging EEG technology to perform high-throughput pharmaco-EEG studies, and our established proprietary Artificial intelligence (AI) and machine learning (ML) approach to develop a novel AI assisted EEG-based drug discovery platform.

The platform helps new medical product (including devices, drugs and biologics) developers prove their experimental products’ safety and efficacy in rodent’s disease models, as mandated by the Food and Drug Administration (FDA, USA) and the National Medical Products Administration (NMPA, China). Our validated and optimised screening platform has high clinical predictivity, which can save time and costs in developing new medical products.